Users blast availability of MedGuides

Share this article:
The FDA's Medication Guide (MedGuide) program was the object of intense criticism from reps of retail pharmacy organizations, consumer groups and academic researchers at a public hearing by the agency in June.

Congressman Michael Ferguson (R-NJ), expressed concern that, although the FDA has authority to require manufacturers to provide MedGuides for selected products, monitoring to assure they are available at pharmacies is largely left to individual state pharmacy boards. He was skeptical that pharmacy boards in every state are assuring compliance or, in some cases, are even aware of their responsibilities in this area. Ferguson urged FDA to grant more “flexibility” in acceptable MedGuide formats and he strongly endorsed the concept of e-distribution.

E-distribution proposals were also endorsed by Tom Lawlor, an executive with the Walgreen Company.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...